Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epelsiban in Adenomyosis
NCT02794467Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Jul 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of epelsiban in adenomyosis (3 arms), sponsored by GSK. Primary endpoints: Mean percent change from baseline in monthly menstrual blood loss at 12 weeks and Number of subjects with adverse events at 3 months. Planned start Jul 2016; status: withdrawn.
02
Drugs
epelsiban
03
Conditions
adenomyosis
Beyond the preview
Go deeper on NCT02794467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794467.